Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.

Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy.

具有非侵袭性边缘区淋巴瘤（nMTCL）的患者，在一线治疗达到完全缓解后，根据疾病进展或下一阶段治疗的时间，被分配到TTR12（≤12个月）组或非TTR12组。

OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score.

总生存分析包括改良里程碑（m-LM）、标准里程碑（s-LM）和时间依赖的Cox（td-Cox），并根据年龄、组织学和T细胞淋巴瘤预后指数（PIT）评分进行了调整。

Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free.

在452名患者中，有165名（36.5%）在12个月内复发，181名（40%）在≥12个月时复发，而106名（23.5%）保持无复发生存。

TTR12 conferred worse OS using m-LM (hazard ratio[HR], 2.14; 95% confidence interval[CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001).

TTR12 通过 m-LM (风险比 [HR], 2.14; 95% 置信区间 [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); 和 td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001) 显示出较差的总生存期(OS)。

Results were consistent in the independent validation cohorts.

在独立验证队列中，结果保持一致。

TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013).

TTR12始终导致无论是否接受前线干细胞移植或PIT评分，外周T细胞淋巴瘤（未特指型）（m-LM：HR，2.32；95% CI，1.51-3.55；P< .001；s-LM：HR，2.10；95% CI，1.33-3.31；P = .001），间变性大细胞淋巴瘤（m-LM：HR，3.34；95% CI，1.18-9.50；P = .023；s-LM：HR，2.96；95% CI，1.02-8.81；P = .046）和血管免疫母细胞性T细胞/滤泡辅助T细胞淋巴瘤（仅m-LM：HR，1.92；95% CI，1.15-3.21；P = .013）的总生存期（OS）更差。

Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407).

仅在TTR12患者中，二线新疗法与化疗相比改善了总生存期（从二线治疗开始到死亡）（HR, 0.60; 95% CI, 0.37-0.97; P = .038；没有TTR12：HR, 0.82; 95% CI, 0.51-1.32; P = .407）。

TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.

TTR12作为预后和潜在的总生存替代标志物，支持对新的风险群体进行分层，并需要对他们进行差异化的治疗。